Acepodia
Acepodia is a clinical-stage biotechnology business that is using its proprietary Antibody-Cell Conjugation (ACC) platform technology to produce first-in-class cell treatments to solve gaps in cancer care. Acepodia employs this live-cell compatible chemistry to attach tumor-targeting antibodies directly to a variety of immune cell receptors, enhancing the lock between immune and cancer cells and generating highly specific, potent cell therapies without the need for genetic engineering. Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targeting a different type of cancer.
Domain
acepodia.com
Country
United StatesIndustry
BiotechnologyEmployees
51-100
Last Funding
$100.0M
Founded
2015
Tech Stack (10 technologies)
Frequently Asked Questions
What technologies does Acepodia use?+
Acepodia uses 10 technologies including Slick, scrollreveal, ScrollMagic.
What industry is Acepodia in?+
Acepodia operates in the Biotechnology industry.
Where is Acepodia based?+
Acepodia is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026